News for Healthcare Capital Corp. (HCCCU)

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ( American: MTNB) today announced the appointment of biotech industry ve

**media[559689]**

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement...

GlycoMimetics to acquire Crescent Biopharma in a strategic merger

BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigation…

Since its 2011 founding, KiwiCo, a STEM-based toy and activity brand, has generated more than $1 billion in revenue, Fortune has exclusively learned.

Alfred Lin, who just celebrated his 14th year at Sequoia Capital, talks about the frameworks he uses to identify outlier startup founders.

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company...

Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and...

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3,...

EVP Capital Announces Agreement for Proposed Qualifying Transaction

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based...

Earnings call: Evogene reports robust growth and strategic partnerships

Jim Creamer Appointed as Interim Chief Financial Officer Clifford Neuman Appointed to Board of Directors Greenwood Village, CO, Dec. 19, 2023 (GLOBE...

- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility...

Mr. Creamer, the Company’s Chief Financial Officer, brings additional public company experience to the company’s Board of Directors. Denver, Colorado,...

Mr. Creamer returns to his former role as the Company’s CFO as the Company continues its push to bring additional experienced management in anticipation of...

Lyra Therapeutics has lost almost 90% of its value since its IPO in 2020. Click here to see why LYRA stock is a Buy.